Compare Align Technology, Inc. (ALGN) vs DexCom, Inc. (DXCM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Align Technology, Inc. vs DexCom, Inc. — how do they compare? Align Technology, Inc. trades at $173.86 (market cap $13.27B), while DexCom, Inc. trades at $73.79 (market cap $28.39B). The key difference: DexCom, Inc. is far larger — about 2.1× Align Technology, Inc.'s market cap. Which is the better fit depends on your goals.
| ALGN | DXCM | |
|---|---|---|
Market Cap | $13.27B | $28.39B |
Sector | Health | Health |
52-Week High | $207.19 | $89.53 |
52-Week Low | $124.88 | $54.84 |
Enterprise Value | $12.32B | $27.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $185.22, up 0.38% today, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Revenue remains stable around $4.0B, supported by a 67.57% gross margin and positive cash flow trends. Recent news highlights global expansion and product innovation, including a new manufacturing facility in India.
Outlook is positive with a $220.75 consensus price target, though risks include regulatory scrutiny from the European Commission and competitive pressures. The stock's valuation at a P/E of 31.65 reflects growth expectations, but investors should monitor execution on international growth and demand stability in North America.
DXCM trades at $73.57, up 3.26% with a bullish technical outlook and strong fundamental performance. Recent earnings beats and FDA clearances for pediatric use of Stelo CGM support growth. Revenue reached $4.66B in 2025 with net income of $836.30M, reflecting a 19.31% margin. Analyst consensus is strongly bullish with an $83.78 price target.
The outlook remains positive driven by CGM market expansion and international growth, though risks include GLP-1 drug competition and execution in non-insulin markets. Valuation at 31.06 P/E is reasonable for its growth profile, with institutional sentiment favoring further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
